SA
AVR

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.3 · elevated volatility

Overview →
11/19/26

Anteris Technologies Global (AVR)

Thursday
3:47 PM ET
ThesisAnteris Technologies Global: the story is balanced — Clinical trial enrollment milestones and interim data readouts from US IDE pivotal trial and European studies

Revenue Outlook

★ Analysts see FY2026 revenue reaching $4M — +88.4% growth in a single year.

What Moves the Stock

  1. 01Clinical trial enrollment milestones and interim data readouts from US IDE pivotal trial and European studies
  2. 02Regulatory progress - FDA breakthrough device designation updates, IDE approval stages, CE Mark submission timing
  3. 03Capital raises and cash runway visibility given -$8M quarterly burn rate and 0.84x current ratio
  4. 04Partnership or licensing announcements for ADAPT technology or commercial distribution rights
  5. 05Competitive TAVR durability data from Edwards/Medtronic that validates or challenges Anteris's differentiation thesis
  6. 06DurAVR TAVR system sales (future - currently pre-commercial)
  7. 07Potential licensing of ADAPT tissue technology to other device manufacturers
  8. 08Surgical valve products using ADAPT technology (future expansion)
FY2025 Snapshot
NI Growth
-23.4%
EPS
$-2.55
1Y Return
+44.9%

AVR Chart

4.66.38.09.711.45.08AVR Daily5.08Jul '26Aug '26Oct '26Nov '26

My Notes

  • growth/speculative - Attracts high-risk biotech investors seeking asymmetric returns from successful clinical development and regulatory…
  • Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (estimated commercialization…
  • Watch on earnings: Monthly cash burn rate and quarters of runway to next financing event, Clinical trial patient enrollment velocity versus targeted timelines, FDA correspondence and regulatory pathway clarity for pivotal trial design.

One Sentence Summary:

Anteris Technologies Global: the story is balanced — clinical trial enrollment milestones and interim data readouts from us ide pivotal trial and european studies.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.